Indivior settles addiction drug dispute with Par

Addiction drug producer Indivior has settled its patent infringement dispute with generics manufacturer Par Pharmaceutical.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Indivior obtains court order to block generic Suboxone

18 June 2018 Addiction treatment drug producer Indivior has obtained a temporary restraining order against Indian generic maker Dr Reddy’s, blocking the company from launching a generic version of Suboxone (buprenorphine and naloxone) Film.

Americas

Indivior pledges to appeal generic Suboxone decision

26 March 2018 UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.

Americas

Indivior to appeal court verdict over Suboxone Film patents

4 September 2017 Indivior, which specialises in addiction treatment drugs, intends to launch an appeal against a US District Court for the District of Delaware verdict that could lead to rival companies selling a generic version of its Suboxone Film, a drug to treat opioid addiction.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Indivior settles addiction drug dispute with Par

More on this story

Editor's picks

Editor's picks

More features